csl

CSL to acquire Chinese blood plasma fractionator

The Australian blood plasma company buys a majority stake in a Chinese firm for $352 million in hopes of broadening its offering in China. It's the first such deal by a foreign firm.

June 13, 2017

CSL and Philips raise a combined $2.2 billion

The successful block trades in CSL and TSMC shares come at a time when the equities markets are traditionally quiet.

August 14, 2008

CSL to buy Talecris Biotherapeutics for $3.1 billion

Australian plasma giant CSL will tap several sources to pay for the purchase of the US company, including a $1.5 billion share placement.

August 13, 2008